ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback